NEW YORK (PRWEB)
September 23, 2020

The Conference Forum is pleased to announce that King-Devick is the winner of DPHARM Idol Disrupt at the 10th annual DPHARM: Disruptive Innovations to Advance Clinical Trials 2020 event. King-Devick technologies is a SaaS model digital/telehealth company that offers a broad set of evidence-based products utilizing integrated technology to accurately and objectively assess eye movement (oculomotor) disorders, such as saccadic dysfunction. These products have been validated in more than 175 recent peer-reviewed published articles in regard to monitoring neurological function in a variety of conditions, including AD, PD, MS, AMD, migraine headache and other neurological conditions.

King-Devick had five minutes to present their innovation and demonstrate how it can disrupt clinical trials to DPHARM Idol’s esteemed panel of judges, with a rigorous Q&A to follow. The judges included:

• Esther Dyson, Executive Founder, Way to Wellville
• Cindy Geoghegan, Patient Advocate
• Yusuf Ghadiali, Senior Director, Global Clinical Operations, Biogen
• Hassan Kadhim, Director, Head of Clinical Trial Business Capabilities, Bristol-Myers Squibb
• Joseph Kim, MBA, Senior Advisor, Clinical Operations and Digital Registry, Digital Health Office, Translational Technology & Innovation, Eli Lilly & Company
• Ülo Palm, MD, PhD, Co-Founder/Chief Medical Officer and Co-Founder, APANDEMIC/Ordaos Bio
• Chandra Ramanathan, PhD, MBA, Global Head, Pharma R&D Open Innovation, Bayer Healthcare
• Douglas Schantz, VP, Clinical Operations, Alexion
• Jessica Scott, MD, JD, Head of R&D Patient Engagement Office, Takeda Pharmaceuticals
• Mark Travers, PhD, MBA, VP, Head of GCTO Regions, Monitoring Excellence, Global Operations, Merck & Co.

“We were really impressed with how King-Devick’s technology uses eye movements as an objective and promising new way to detect abnormalities in hard to diagnose neurological diseases, and the broad applications for scientific advancement and improved care in many prevalent and difficult disease areas,” said DPHARM Idol judge Jessica Scott, Takeda Pharmaceuticals, when asked to elaborate on the judges’ reasoning.

Patient advocate and DPHARM Idol judge Cindy Geoghegan added, “The judging for this year’s DPHARM IDOL was especially close, with so many of the competing companies demonstrating technology that is not just envisioned, but that is already being applied in clinical research in innovative ways. King-Devick was chosen as this year’s winner because it provides a validated solution to a major challenge, the ability to measure neurological function in real-time, which has the potential to transform the ability to do research in therapeutic areas (such as AD, PD, MS, AMD, Migraine headache and others).”

Although they were triumphant, King-Devick had strong competition from the other DPHARM Idol Disrupt presenters:

Proof Pilot – Matt Amsden, CEO and Founder

Obvio Health – Susan Dallabrida, PhD, VP, Consultancy

Root Health – Raj Sharma, President and CEO

Trial Scope – Mike Wenger, VP, Patient Engagement

“All of the contenders generated enthusiasm and strong interest from judges on the panel, each providing innovative solutions to real challenges in drug development,” said the DPHARM Idol Disrupt 2020 judges.

The annual DPHARM: Disruptive Innovations to Advance Clinical Trials conference, organized by the Conference Forum, reports on industry and out of industry innovation and how to change the paradigm of clinical trials to reduce the burden to patients and investigators, streamline processes and ultimately get therapeutics to patients faster. Now in its 10th year, DPHARM connects pharma, biotech, clinical research partners and patient advocacy to inspire and encourage the most innovative technologies and ideas in clinical trials and drug development. Mark your calendars for next year’s event, to be held on September 28-29, 2021 in Boston.

Share article on social media or email: